ML20006B571

From kanterella
Jump to navigation Jump to search
Ack Receipt of Transmitting Correspondence from Constituent MR Habibian in Support of Petition for Rulemaking to Revise 10CFR35.NRC Currently Reexamining Regulations Re Use of Radiopharms in Nuclear Medicine
ML20006B571
Person / Time
Issue date: 01/11/1990
From: Rathbun D
NRC OFFICE OF GOVERNMENTAL & PUBLIC AFFAIRS (GPA)
To: Clement B
HOUSE OF REP.
Shared Package
ML20006B572 List:
References
RULE-PRM-35-9 CCS, NUDOCS 9002050087
Download: ML20006B571 (2)


Text

..,

~\\

uselTO states

/

NUCLEAR RESULATORY COMMi&8 ION n

{

j wAemworoes. o. c. aeans 8

  • k...,.,

January 11, 1990 The Honorable Bob Clement j

Unitec States House of Representatives i

Washington, D. C.

20515

Dear Congressman Clement:

This is to acknowledge receipt of your letter dated December 20, 1989, transmitting correspondence f rom your constituent Dr. M. R. Habibian, in support of a petition for rulemaking to revise 10 CFR 35 Regulations.

l

+

l The petition for rulemaking was submitted to the Nuclear Regulatory l

l Commission (NRC) by the American College of Nuclear Physicians and the i

Society of Nuclear Medicine. The petitioners requested that the NRC l

modify current regulations to allow:

(a) the use of radiopharmaceuticals l

for therapeutic indications not listed in the package insert (diagnostic i

indications are not restricted by current regulations).. (b) deviations j

from the manufacturer's instructions in preparing radiopharmaceuticals, and(c)compoundingradiopharmaceuticalsfromreagentchemicals.

}

The NRC published a Federal Register notice (54 FR 38239 September 15, 1989), announcing receipt of the petition and providing a 90-day public comment period. We have received more than 400 consent letters.

In light of the information: submitted by the petitioners and the commenters, the NRC is currently reexamining its regulations governing the i

l use of radiopharmacauticals in nuclear medicine. The issues raised will L

be addressed in a rulemaking proceeding specifically designed to resolve the petition. During this rulemaking process, the NRC will consult with the Food and Drug Administration, which approves the package' inserts and i

the i.anufacturer's instructions, and the State Boards;of Pharmacy and.

invite their views regarding the resolution of this petition.

f I want to assure you that the connents of your constituent will be-l considered along with the others in reexamining our regulations. However, it would be premature to predict the outcome of the reexamination before completion of the rulemaking proceeding, I trust this information is responsive to your request.

Sincerely, M

R/((IE%TAggjjSCN/

Dennis K. Rathbun, Director Congressional Affairs Office of Governnental and Public Affairs 9002050087 900111 p

PDR PRl1 (C d 35-9 PDC I

r>.

- s-N.

I

]

%Pms i

l t

K octA t

1 i

i k

1 f

Y t

1 i

i I

l

+

j 3

l i

I Q

I Letter also verbally approved by Jim Blaha and Mike Weter (per Dennis Rathbun/Betsy Keeling) 9/t.> /-//- 94

{

I i

)

5 A

l l

+

,x----~+~,,,r-,,,-ow.,-,,--,--n----n,n.m.

,,n--,,,,w._n,,,

,,,,,n,m

.,,-.,-,,_nn_-n..a.

---. - ~ ~ - _ _ -.... ~ - - - ~ ~, - - -... - - - -

.